
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure Inc. has reported an impressive EBITDA margin of 11.3%, reflecting a significant year-over-year increase of 460 basis points that surpassed market expectations. Although its gross margin experienced a slight contraction, the company's operating margin improved by 160 basis points, aligning well with positive consensus estimates. Growth drivers such as stronger sales from key products, including EPi-Sense and newer offerings like CryoSPHERE and EnCompass, suggest that AtriCure is positioned for continued strong performance and enhanced profitability.
Bears say
AtriCure Inc. is facing several challenges contributing to a negative outlook, including disappointing sales projections in key product categories such as Minimally Invasive Ablation and Appendage Management, which could result in revenue growth slowing to below 11%. Furthermore, the company is exposed to competitive pressures, particularly from Medtronic's Penditure surgical LAA closure device, which threatens its market share and may hinder future sales performance. Despite an increase in operating and adjusted EBITDA margins, a decline in gross margin, alongside the potential for weaker than anticipated profitability and ongoing market competition, raises concerns about financial stability and growth prospects.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares